Umecrine Cognition

Umecrine Cognition Develops Drugs for Central Nervous System Diseases, CNS Caused by Endogenous CNS Active Steroids (GABA Steroids).Umecrine Cognition is a lean organization within a capable network. The company was established in 2006 as a subsidiary of Umecrine AB to focus on development activities aimed at finding treatments for neurological disorders in the central nervous system caused by endogenous CNS active steroids (GABA-steroids).The GABA system is the primary inhibitory neurotransmitter system within the central nervous system, and excessive GABAergic tone has been described in several important clinical conditions such as hepatic encephalopathy, Alzheimer's disease, and Down syndrome. Certain endogenous GABA-steroids act as potent agonists on GABAA receptors, and changes in the production and metabolism of these GABA-steroids have been described in hepatic encephalopathy, Alzheimer's disease, and Down syndrome.The company is dedicated to developing and commercializing treatments for hepatic encephalopathy in patients with liver disease.